Labcorp Holdings Inc.
Labcorp Holdings Inc. (LH)
Overview
Labcorp Holdings is one of the largest clinical laboratory and drug-development services companies in the world, headquartered in Burlington, North Carolina. Tracing its roots to Roche Biomedical Laboratories (founded 1978) and formed in its current shape through a 1995 merger, Labcorp sits in the Health Care sector under Life Sciences/Diagnostics & Research, operates in more than 100 countries (with the large majority of its business concentrated in the U.S.), and employs roughly 70,000-71,000 people. The company generates about $14 billion in annual revenue, running one of the largest clinical laboratory testing networks anywhere, processing well over 160 million patient tests a year through a national network of patient service centers and central labs.
What They Do & How They Make Money
Labcorp makes money primarily by running medical laboratory tests on behalf of physicians, hospitals, health systems, and patients, then billing insurers, government payers (Medicare/Medicaid), employers, or patients directly for each test performed — a high-volume, relatively low-margin-per-test business that depends on scale, automation, and an extensive network of roughly 2,000 patient service centers and thousands of phlebotomists to draw samples close to where patients live. Beyond routine bloodwork, cholesterol panels, and urinalysis, the company runs increasingly sophisticated specialty and esoteric testing — oncology diagnostics, genomic and molecular testing, infectious disease testing, forensic and paternity DNA testing, toxicology and pain-management drug monitoring, and newer high-value tests such as its FDA-cleared blood test for Alzheimer's-related amyloid pathology. A second, distinct revenue stream comes from its Biopharma Laboratory Services business, which contracts with pharmaceutical, biotechnology, and medical-device companies to run the laboratory testing and central-lab work that underpins clinical trials and drug development — work so central to the industry that Labcorp says its testing supported the large majority of new FDA drug approvals in recent years. This combination gives Labcorp two related but distinct customer bases: everyday patients and healthcare providers on one side, and pharma/biotech R&D departments on the other.
Business Segments
Labcorp reports two segments:
- Diagnostics Laboratories (Dx) — the larger segment by far, generating roughly $11.2 billion in trailing-twelve-month revenue (about 78% of the total). This is the core clinical-testing business serving physicians, hospitals, employers, and patients directly, spanning routine lab work through specialty oncology, genetic, and infectious-disease testing, along with consumer-facing at-home test kits.
- Biopharma Laboratory Services (BLS) — roughly $3.2 billion in trailing-twelve-month revenue (about 22% of the total), providing central laboratory testing, biomarker analysis, and related scientific support services to pharmaceutical, biotech, and medical-device companies running clinical trials. Labcorp spun off its separate clinical-trial-management (CRO) business, Fortrea, as an independent public company in 2023, leaving BLS focused specifically on the lab-testing piece of drug development rather than full trial management.
Total revenue has grown steadily, from about $11.9 billion in FY2022 to roughly $14.0 billion in FY2025, with net income recovering strongly after a soft 2023 to reach nearly $1 billion on a trailing basis, aided by acquisitions (including Invitae's assets in 2024 and Personal Genome Diagnostics in 2022) that have expanded its genomic and oncology testing capabilities.
Competitors
- Quest Diagnostics — Labcorp's closest and largest direct competitor, operating a similarly scaled national clinical laboratory network and competing head-to-head for insurer contracts, hospital lab-outsourcing deals, and patient volume
- Hospital and health-system in-house labs — many large hospital systems run their own laboratories for routine testing, competing for volume that would otherwise go to Labcorp
- Sonic Healthcare, BioReference Laboratories, and regional/specialty lab companies — smaller but meaningful competitors in specific geographies or specialty testing niches
- IQVIA, Charles River Laboratories, ICON plc, and Fortrea (its own former CRO spinoff) — competitors in the biopharma/clinical-trial-support side of the business, including central-lab and biomarker-testing services
- Emerging genomics and direct-to-consumer testing companies (e.g., genetic testing startups) — competitors and occasional acquisition targets in molecular and genomic diagnostics
Competitive Position
Labcorp's principal moat is scale and network density: its national footprint of patient service centers and its logistics network for collecting and transporting specimens are extremely expensive and slow to replicate, giving it strong negotiating leverage with health insurers and large national contracts with employers and health systems. Decades of accumulated regulatory approvals, laboratory accreditations, and payer relationships create high barriers to entry, and its Biopharma Laboratory Services arm benefits from deep, sticky relationships with pharmaceutical companies that value a lab partner capable of supporting global drug trials at scale — a position reinforced by the claim that its testing has supported the vast majority of recent FDA drug approvals. The two-segment structure also provides some diversification: routine diagnostics testing is a steady, demand-driven annuity-like business tied to population health needs, while biopharma services benefit from R&D spending cycles in the drug industry, which move somewhat independently of consumer healthcare utilization.
Key risks include reimbursement pressure — government and private insurers continually push to reduce per-test payment rates, squeezing margins on Labcorp's high-volume, commoditized routine tests — along with the capital intensity of maintaining its lab and logistics network, litigation and regulatory scrutiny around billing practices, data privacy, and quality control (an area where the company has faced periodic criticism), and competitive pressure from both Quest Diagnostics and lower-cost in-house hospital labs. The company's continued push into higher-value specialty and genomic testing (like its Alzheimer's blood test and oncology companion diagnostics) is a strategic response aimed at improving margins and differentiating from commoditized routine testing, but successful execution depends on continued innovation, FDA approvals, and payer adoption of newer, more expensive tests.